Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's ...
Hims & Hers and other telehealth providers say employers that balked at pricey brand-name shots are investigating cheaper off ...
Hims is pushing back on the idea that compounded injections aren’t as safe or beneficial as the brand-name drugs sold by Novo and Eli Lilly & Co., even as those companies turn to the courts and the ...
Telehealth companies Hims & Hers Health Inc., Noom Inc. and Sesame Inc. have lured individual customers with low-cost versions of popular weight-loss shots like Ozempic and Wegovy. Now, they’re going ...
Novo Nordisk NVO has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of ...
Telehealth companies selling low-cost, compounded versions of popular weight-loss drugs, including Ozempic and Wegovy, are drawing increased interest from employers, Bloomberg reported Oct. 29.
A mong the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for ...
Compounded semaglutide can be an affordable alternative to brand-name weight loss injections like Ozempic and Wegovy. But ...
Hims & Hers is taking a more serious approach to its latest campaign. The telehealth company, which is best known for its ...
Health and wellness company Hims & Hers announced Monday that it is introducing injectable weight-loss drugs at a fraction of the cost of Ozempic and Wegovy. Hims & Hers Health stock declined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback